tbuckley/cabot-search huggingface dataset:
Global antimicrobial-resistance drivers: an ecological country-level study at the human–animal interface
Authors: Kasim Allel, Lucy Day, Alisa Hamilton, Leesa Lin, Luis Furuya-Kanamori, Catrin E Moore, Thomas Van Boeckel, Ramanan Laxminarayan, Laith Yakob
Journal: The Lancet Planetary Health (2023)

BackgroundAntimicrobial resistance (AMR) is a pressing, holistic, and multisectoral challenge facing contemporary global health. In this study we assessed the associations between socioeconomic, anthropogenic, and environmental indicators and country-level rates of AMR in humans and food-producing animals.MethodsIn this modelling study, we obtained data on Carbapenem-resistant Acinetobacter baumanii and Pseudomonas aeruginosa, third generation cephalosporins-resistant Escherichia coli and Klebsiella pneumoniae, oxacillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium AMR in humans and food-producing animals from publicly available sources, including WHO, World Bank, and Center for Disease Dynamics Economics and Policy. AMR in food-producing animals presented a combined prevalence of AMR exposure in cattle, pigs, and chickens. We used multivariable β regression models to determine the adjusted association between human and food-producing animal AMR rates and an array of ecological country-level indicators. Human AMR rates were classified according to the WHO priority pathogens list and antibiotic–bacterium pairs.FindingsSignificant associations were identified between animal antimicrobial consumption and AMR in food-producing animals (OR 1·05 [95% CI 1·01–1·10]; p=0·013), and between human antimicrobial consumption and AMR specifically in WHO critical priority (1·06 [1·00–1·12]; p=0·035) and high priority (1·22 [1·09–1·37]; p<0·0001) pathogens. Bidirectional associations were also found: animal antibiotic consumption was positively linked with resistance in critical priority human pathogens (1·07 [1·01–1·13]; p=0·020) and human antibiotic consumption was positively linked with animal AMR (1·05 [1·01–1·09]; p=0·010). Carbapenem-resistant Acinetobacter baumanii, third generation cephalosporins-resistant Escherichia coli, and oxacillin-resistant Staphylococcus aureus all had significant associations with animal antibiotic consumption. Analyses also suggested significant roles of socioeconomics, including governance on AMR rates in humans and animals.InterpretationReduced rates of antibiotic consumption alone will not be sufficient to combat the rising worldwide prevalence of AMR. Control methods should focus on poverty reduction and aim to prevent AMR transmission across different One Health domains while accounting for domain-specific risk factors. The levelling up of livestock surveillance systems to better match those reporting on human AMR, and, strengthening all surveillance efforts, particularly in low-income and middle-income countries, are pressing priorities.FundingNone.
Global governance for pandemic prevention and the wildlife trade
Authors: Eduardo Gallo-Cajiao, Susan Lieberman, Nives Dolšak, Aseem Prakash, Ronald Labonté, Duan Biggs, Christine Franklin, Tiffany H Morrison, A M Viens, Richard A Fuller, Raphael Aguiar, Pedro Fidelman, James E M Watson, Cécile Aenishaenslin, Mary Wiktorowicz
Journal: The Lancet Planetary Health (2023)

Although ideas about preventive actions for pandemics have been advanced during the COVID-19 crisis, there has been little consideration for how they can be operationalised through governance structures within the context of the wildlife trade for human consumption. To date, pandemic governance has mostly focused on outbreak surveillance, containment, and response rather than on avoiding zoonotic spillovers in the first place. However, given the acceleration of globalisation, a paradigm shift towards prevention of zoonotic spillovers is warranted as containment of outbreaks becomes unfeasible. Here, we consider the current institutional landscape for pandemic prevention in light of ongoing negotiations of a so-called pandemic treaty and how prevention of zoonotic spillovers from the wildlife trade for human consumption could be incorporated. We argue that such an institutional arrangement should be explicit about zoonotic spillover prevention and focus on improving coordination across four policy domains, namely public health, biodiversity conservation, food security, and trade. We posit that this pandemic treaty should include four interacting goals in relation to prevention of zoonotic spillovers from the wildlife trade for human consumption: risk understanding, risk assessment, risk reduction, and enabling funding. Despite the need to keep political attention on addressing the current pandemic, society cannot afford to miss the opportunity of the current crisis to encourage institution building for preventing future pandemics.
Optimization of the allergen classification of the International Classification Of Diseases, 11th Revision (ICD-11)
Authors: Luciana Kase Tanno, Yann Briand, Mélissa Mary, David A. Khan, James L. Sublett, Mark L. Corbett, Ruby Pawankar, Stefano Del Giacco, Maria Jose Torres, Ignacio J. Ansontegui, Motohiro Ebisawa, Bryan Martin, Pascal Demoly
Journal: Journal of Allergy and Clinical Immunology (2023)
199P Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET) and V-ATPase
Authors: R. Rosell, J.L. Gómez-Vázquez, E. Jantus Lewintre, M. Ito, P. Cao, X. Cai, B. Xing, S. Calabuig Fariñas, A.F. Cardona, J.K. Rodríguez, M. Marco Jordán, C. Pedraz Valdunciel, M.A. Molina-Vila, J. Codony-Servat, Z. Dantes, A. Aguilar, I.G. Sullivan, I. Moya Horno, L. Cirera, M. Gonzalez-Cao
Journal: Journal of Thoracic Oncology (2023)
186P Elevated CXCL10:IL-8 ratio in bronchoalveolar lavage fluid of immune checkpoint inhibitor-related pneumonitis
Authors: P.T.L. Van Mol, A. Franken, S. Vanmassenhove, E. Donders, R. Schepers, T. van Brussel, C. Dooms, J. Yserbyt, N. De Crem, D. Testelmans, W. de Wever, K.L. Nackaerts, J.F. Vansteenkiste, R. Vos, D. Lambrechts, J. Naidoo, K. Suresh, S. Humblet-Baron, E. Wauters
Journal: Journal of Thoracic Oncology (2023)
201P RNA-based plus DNA-based analysis of METexon 14 skipping in a non-small cell lung cancer increases diagnostic performance
Authors: P.R.M. De Marchi, F.L.V. Visani, T.C. Montella, L. Delmonico, F.C. Koyama, C.B. Fernandes, F.O.R. Do Rego, L.T. Galindo, B.B. de Souza, C. Leslin, N. Afonso, I.S. Negreiros, P.N. Aguiar Junior, C.M.D.C. Mathias, L.M. Da Silva, E.M. Pereira, M.G. Zalis, C.G.M. Ferreira, R. Dienstmann
Journal: Journal of Thoracic Oncology (2023)
145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study
Authors: D.P. Carbone, S.N. Waqar, J. Chaft, M.G. Kris, B.E. Johnson, J.M. Lee, I.I. Wistuba, D. Kwiatkowski, P.A. Bunn, K. Schulze, A.M. Johnson, E. Brandao, M. Awad, K. Reckamp, A.C. Chiang, A. Nicholas, V. Rusch
Journal: Journal of Thoracic Oncology (2023)
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC
Authors: G. Mazzaschi, G. Bocchialini, B. Lorusso, M. Pluchino, F. Trentini, G. Di Rienzo, S. Cattadori, L. Moron Dalla Tor, M. Verzè, R. Minari, P. Bordi, A. Leonetti, S. D’Agnelli, G. Milanese, L. Leo, L. Gnetti, G. Roti, L. Ampollini, F. Quaini, N. Sverzellati, M. Tiseo
Journal: Journal of Thoracic Oncology (2023)
164P Immune cells distribution and spatial relationship within microenvironment as predictive biomarkers of benefit in extended stage small cell lung cancer patients receiving atezolizumab plus carboplatin and etoposide as first-line treatment
Authors: G. Pasello, M. Lorenzi, A. Tosi, A. Roma, A. Pavan, A. Scapinello, S. Lonardi, A. Ferro, A. Dal Maso, S. Frega, L. Bonanno, P. Del Bianco, V. Guarneri, A. Rosato
Journal: Journal of Thoracic Oncology (2023)
87P Prognostic models of recurrence-free survival in non-small cell lung cancer
Authors: K.R. Palmer, A. Houston, H. Macpherson, W. Wang, F. Quartly, M. Grant, K.R. Patel, A. Ghose, S. Williams, L. Lim Farah, J. Conibear, K. Giaslakiotis, K. Lau, W. Ricketts, A. Januszewski
Journal: Journal of Thoracic Oncology (2023)
165P SCLC subtypes are associated with distinct dinicopathological features and outcomes: A biomarker analysis from the CANTABRICO study
Authors: P. Rocha, I. Sanchez, L. Masfarre Pinto, M. Giner, N. Navarro Gorro, A. Rios Hoyo, A. Taus Garcia, S. Pérez-Buira, É. Torres-Fernandez, S. Clave, B. Bellosillo Paricio, F. Rojo, L. Paz-Ares, C. Martí Cubells, C. Aguado de la Rosa, M.D. Isla Casado, R. Garcia-Campelo, L. Baez, Á. Callejo Mellén, E. Arriola
Journal: Journal of Thoracic Oncology (2023)
82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies
Authors: A.G. Gianoukakis, S.M. Arnold, S.A. Kahn, M. Taylor, E. Garralda, M.G. Krebs, H-T. Arkenau, L. Clark, G. Fisher, V. Subbiah
Journal: Journal of Thoracic Oncology (2023)
167P Five-years incidence of SCLC and analysis of PM2.5 air pollution in the province of Brescia: Preliminary results
Authors: S. Grisanti, P. Borghetti, S. Bianchi, C. Vultaggio, M. Mandruzzato, G. Facheris, E. Fassi, L.C. Ammoni, A. Baggi, M. Meazza Prina, S.M. Magrini, A. Berruti
Journal: Journal of Thoracic Oncology (2023)
126P Chemotherapy and stereotactic ablative radiotherapy in newly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for concurrent radiochemotherapy: Sub-analysis and update of START-NEW-ERA non-randomised phase II trial
Authors: F. Arcidiacono, P. Anselmo, M. Casale, C. Zannori, F. Loreti, M. Italiani, B. Enrico, S. Fabiani, G. Marchetti, V. Tassi, F.A. Mancioli, M. Muti, A. Guida, S. Bracarda, M. Ragusa, E. Maranzano, F. Trippa
Journal: Journal of Thoracic Oncology (2023)
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials
Authors: Andrew Blauvelt, Mark Lebwohl, Richard G. Langley, Katelyn Rowland, Ya-Wen Yang, Daphne Chan, Megan Miller, Yin You, Jenny Yu, Diamant Thaҫi, Peter Foley, Kim A. Papp
Journal: Journal of the American Academy of Dermatology (2023)

Malignancy risk surveillance among patients receiving long-term immunomodulatory psoriasis treatments remains an important safety objective.To report malignancy rates in patients with moderate-to-severe psoriasis treated with guselkumab for up to 5 years versus general and psoriasis patient populations.Cumulative rates of malignancies/100 patient-years (PY) were evaluated in 1721 guselkumab-treated patients from VOYAGE 1 and 2. Malignancy rates (excluding nonmelanoma skin cancer [NMSC]) were compared with rates in the Psoriasis Longitudinal Assessment and Registry. Standardized incidence ratios comparing malignancy rates (excluding NMSC and cervical cancer in situ) between guselkumab-treated patients and the general US population using Surveillance, Epidemiology, and End Results data were calculated, adjusting for age, sex, and race.Of 1721 guselkumab-treated patients (>7100 PY), 24 had NMSC (0.34/100PY; basal:squamous cell carcinoma ratio, 2.2:1), and 32 had malignancies excluding NMSC (0.45/100PY). For comparison, the malignancy rate excluding NMSC was 0.68/100PY in the Psoriasis Longitudinal Assessment and Registry. Malignancy rates (excluding NMSC/cervical cancer in situ) in guselkumab-treated patients were consistent with those expected in the general US population (standardized incidence ratio = 0.93).Inherent imprecision in determining malignancy rates.In patients treated with guselkumab for up to 5 years, malignancy rates were low and generally consistent with rates in general and psoriasis patient populations.
192P ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations
Authors: P.L.S. Saw, G.S. Tan, A. Tan, G. Lai, W.C. Tan, E.H. Tan, M-K. Ang, D.W-T. Lim, R. Kanesvaran, Q.S. Ng, A. Jain, W.L. Tan, T. Rajasekaran, J. Chan, Y.L. Teh, S.H. Tan, T.K.H. Lim, D.S.W. Tan
Journal: Journal of Thoracic Oncology (2023)
133TiP Neoadjuvant osimertinib followed by sequential definitive radiotherapy and/or surgery in stage III EGFR-mutant NSCLC: An open-label, single-arm, phase II study
Authors: W. Kian, N. Peled, L.C. Roisman, E. Levison, J. Dudnik, E. Chernomordikov, E. Dudnik, S. Keren-Rosenberg, S. Tsuriel, V. Hannes, D. Hershkovitz, R. Lichtenberg, I. Granot, B. Krayim, W. Shalata, A.M. Allen, P. Blumenfeld, K. Lavrenkov
Journal: Journal of Thoracic Oncology (2023)
41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)
Authors: H. Borghaei, D. Balli, L. Paz-Ares, M. Reck, S.S. Ramalingam, J.R. Brahmer, T-E. Ciuleanu, A. Pluzanski, J-S. Lee, J. Gainor, M. Schenker, A. Schoenfeld, R. Bernabe Caro, N. Ready, K.H. Lee, B. Zurawski, C. Audigier-Valette, V. Baxi, W. Geese, K.J. O’Byrne
Journal: Journal of Thoracic Oncology (2023)
159P Optimization and validation of a circulating microRNA biomarker panel for early detection of lung cancer in a Japanese population
Authors: J. Samejima, J. Okami, Y. Tanaka, S. Kobayashi, T. Kimura, M. Mukai, T. Nagao, H. Matsuoka, M. Tsuboi
Journal: Journal of Thoracic Oncology (2023)
Centrally Adjudicated Heart Failure Outcomes Are Needed in Clinical Trials
Authors: Akshay S. Desai, Mark C. Petrie
Journal: JACC Heart Failure (2023)

The U.S. heart allocation system ranks candidates with only 6 treatment-based categorical “statuses” and ignores many objective patient characteristics.This study sought to determine the effectiveness of the standard 6-status ranking system and several novel prediction models in identifying the most urgent heart transplant candidates.The primary outcome was death before receipt of a heart transplant. The accuracy of the 6-status system was evaluated using Harrell’s C-index and log-rank tests of Kaplan-Meier estimated survival by status for candidates listed postpolicy (November 2018 to March 2020) in the Scientific Registry of Transplant Recipients data set. The authors then developed Cox proportional hazards models and random survival forest models using prepolicy data (2010-2017). The predictor variables included age, diagnosis, laboratory measurements, hemodynamics, and supportive treatment at the time of listing. The performance of these models was compared with the candidate’s 6-status ranking in the postpolicy data.Since policy implementation, the 6-status ranking at listing has had moderate ability to rank-order candidates (C-index: 0.67). Statuses 4 and 6 had no significant difference in survival (P = 0.80), and status 5 had lower survival than status 4 (P < 0.001). Novel multivariable prediction models derived with prepolicy data ranked candidates correctly more often than the 6-status rankings (Cox proportional hazards model C-index: 0.76; random survival forest model C-index: 0.74). Objective physiologic measurements, such as glomerular filtration rate, had high variable importance.The treatment-based 6-status heart allocation system has only moderate ability to rank-order candidates by medical urgency. Predictive models that incorporate physiologic measurements can more effectively rank-order heart transplant candidates by urgency.
Cold temperature extends longevity and prevents disease-related protein aggregation through PA28γ-induced proteasomes
Authors: Hyun Ju Lee, Hafiza Alirzayeva, Seda Koyuncu, Amirabbas Rueber, Alireza Noormohammadi, David Vilchez
Journal: Nature Aging (2023)

Abstract Aging is a primary risk factor for neurodegenerative disorders that involve protein aggregation. Because lowering body temperature is one of the most effective mechanisms to extend longevity in both poikilotherms and homeotherms, a better understanding of cold-induced changes can lead to converging modifiers of pathological protein aggregation. Here, we find that cold temperature (15 °C) selectively induces the trypsin-like activity of the proteasome in Caenorhabditis elegans through PSME-3, the worm orthologue of human PA28γ/PSME3. This proteasome activator is required for cold-induced longevity and ameliorates age-related deficits in protein degradation. Moreover, cold-induced PA28γ/PSME-3 diminishes protein aggregation in C. elegans models of age-related diseases such as Huntington’s and amyotrophic lateral sclerosis. Notably, exposure of human cells to moderate cold temperature (36 °C) also activates trypsin-like activity through PA28γ/PSME3, reducing disease-related protein aggregation and neurodegeneration. Together, our findings reveal a beneficial role of cold temperature that crosses evolutionary boundaries with potential implications for multi-disease prevention.
36P Prevalence, clinical characteristics, and treatment outcomes of patients with BRAF-mutated advanced NSCLC in China: A real-world multi-center study
Authors: B. Jia, J. Zhao, B. Jin, F. Zhang, S. Wang, L. Zhang, Z. Wang, T. An, Y. Wang, M. Zhuo, J. Li, X. Yang, S. Li, H. Chen, Y. Chi, J. Wang, X. Zhai, Y. Tai, Y. Liu, G. Guan
Journal: Journal of Thoracic Oncology (2023)
92P Predictors, surrogate and patient-reported outcomes in neoadjuvant immunotherapy for lung cancer: A single-center retrospective study
Authors: L. Bertolaccini, S. Mohamed, D. Galetta, F. Petrella, M. Casiraghi, C. Diotti, A. Mazzella, G. Lo Iacono, L. Girelli, G. Sedda, F. de Marinis, L. Spaggiari
Journal: Journal of Thoracic Oncology (2023)
91P Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study
Authors: S. Lin, D. Kahangire, S. Nagar, M-J. Ahn, R. Affi, J. Agulnik, J-Y. Shih, M.J. Hochmair, A. Tufman, D. Debieuvre, J. Chow, M. Jimenez, K. Davis, M. Sandelin, R. Veluswamy
Journal: Journal of Thoracic Oncology (2023)
Using the Saltshaker
Authors: Franz H. Messerli, Evgeniya V. Shalaeva
Journal: Journal of the American College of Cardiology (2023)

Angiotensinogen is the proximal precursor of the angiotensin peptide hormones of the renin-angiotensin-aldosterone system (RAAS). Clinical trials are ongoing targeting angiotensinogen for the treatment of hypertension and heart failure. The epidemiology of angiotensinogen is not well defined, particularly its relationship to ethnicity, sex, and blood pressure (BP)/hypertension.The authors sought to determine the relationship of circulating angiotensinogen levels to ethnicity, sex, BP, incident hypertension, and prevalent hypertension in a modern sex-balanced ethnically diverse cohort.Plasma angiotensinogen levels were measured in 5,786 participants from the MESA (Multi-Ethnic Study of Atherosclerosis). Linear, logistic, and Cox proportional hazards models were utilized to examine the associations of angiotensinogen with BP, prevalent hypertension, and incident hypertension, respectively.Angiotensinogen levels were significantly higher in females than males and differed across self-reported ethnicities with the ordering (from highest to lowest): White, Black, Hispanic, and Chinese adults. Higher levels were associated with higher BP and odds of prevalent hypertension, after adjusting for other risk factors. Equivalent relative differences in angiotensinogen were associated with greater differences in BP in males vs females. In males not taking RAAS-blocking medications, a standard deviation increment in log-angiotensinogen was associated with 2.61 mm Hg higher systolic BP (95% CI: 1.49-3.80), while in females the same increment in angiotensinogen was associated with 0.97 mm Hg higher systolic BP (95% CI: 0.30-1.65).Significant differences in angiotensinogen levels are present between sexes and ethnicities. A positive association is present between levels and prevalent hypertension and BP, which differs between sexes.
134P Clinical and epidemiological patterns of pleural mesothelioma in the United States: Long-term data from SEER database
Authors: M. Mohamed Shawqi, L.N. Sherif, A.A. Bahbah, A.H. Allam, M.T. Khallafallah, O.A. Aboshady
Journal: Journal of Thoracic Oncology (2023)
Assessing and Addressing Social Determinants of Cardiovascular Health
Authors: Eric J. Brandt, Kardie Tobb, Julia C. Cambron, Keith Ferdinand, Paul Douglass, Patricia K. Nguyen, Krishnaswami Vijayaraghavan, Sabrina Islam, Ritu Thamman, Shahid Rahman, Akshay Pendyal, Nishtha Sareen, Celina Yong, Latha Palaniappan, Uzoma Ibebuogu, Andrew Tran, Adrian M. Bacong, Gina Lundberg, Karol Watson
Journal: Journal of the American College of Cardiology (2023)
114M0 First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3
Authors: E. Kalinka, I. Bondarenko, M. Gogishvili, T. Melkadze, A. Baramidze, A. Sezer, T. Makharadze, S. Kilickap, M. Gumus, K.D. Penkov, D. Giorgadze, M. Özgüroğlu, X. He, J-F. Pouliot, F. Seebach, I. Lowy, G. Gullo, P. Rietschel
Journal: Journal of Thoracic Oncology (2023)
109P Setting up 4D-CT based image guided radiotherapy (IGRT) for locally advanced lung cancer: Is it safe to reduce PTV margin for dosimetric benefit?
Authors: A. Saha, A. Mishra, S. Manna, T. Ghosh, J. Bhattacharya, S. Goswami, L.N. Biswas, S. Mitra, B. Sarkar, A. Banik, S.R. Chowdhury, S. Biswal, S. Mandal, K. George, P. Soren, M. Gazi
Journal: Journal of Thoracic Oncology (2023)
Autism in England: assessing underdiagnosis in a population-based cohort study of prospectively collected primary care data
Authors: Elizabeth O'Nions, Irene Petersen, Joshua E.J. Buckman, Rebecca Charlton, Claudia Cooper, Anne Corbett, Francesca Happé, Jill Manthorpe, Marcus Richards, Rob Saunders, Cathy Zanker, Will Mandy, Joshua Stott
Journal: The Lancet Regional Health - Europe (2023)

Autism has long been viewed as a paediatric condition, meaning that many autistic adults missed out on a diagnosis as children when autism was little known. We estimated numbers of diagnosed and undiagnosed autistic people in England, and examined how diagnostic rates differed by socio-demographic factors.This population-based cohort study of prospectively collected primary care data from IQVIA Medical Research Data (IMRD) compared the prevalence of diagnosed autism to community prevalence to estimate underdiagnosis. 602,433 individuals registered at an English primary care practice in 2018 and 5,586,100 individuals registered between 2000 and 2018 were included.Rates of diagnosed autism in children/young people were much higher than in adults/older adults. As of 2018, 2.94% of 10- to 14-year-olds had a diagnosis (1 in 34), vs. 0.02% aged 70+ (1 in 6000). Exploratory projections based on these data suggest that, as of 2018, 463,500 people (0.82% of the English population) may have been diagnosed autistic, and between 435,700 and 1,197,300 may be autistic and undiagnosed (59-72% of autistic people, 0.77%-2.12% of the English population). Age-related inequalities were also evident in new diagnoses (incidence): c.1 in 250 5- to 9-year-olds had a newly-recorded autism diagnosis in 2018, vs. c.1 in 4000 20- to 49-year-olds, and c.1 in 18,000 people aged 50+.Substantial age-related differences in the proportions of people diagnosed suggest an urgent need to improve access to adult autism diagnostic services.Dunhill Medical Trust, Economic and Social Research Council, Medical Research Council, National Institute for Health Research, the Wellcome Trust, and the Royal College of Psychiatrists.
79TiP Progress of a phase I trial (TOTEM) of repotrectinib in combination with osimertinib in advanced, metastatic EGFR mutant NSCLC
Authors: A. Aguilar, M. Cobo, A. Azkarate, A. Calles, M. Gonzalez-Cao, A. Cantero, J. Terrasa, R. Álvarez, M.Á. Molina, R. Rosell
Journal: Journal of Thoracic Oncology (2023)
16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial
Authors: R.A. Soo, U. Dafni, J-Y. Han, B.C. Cho, E. Nadal, C.M. Yeo, E. Carcereny, J. de Castro, M.A. Sala Gonzalez, L. Coate, M. Provencio Pulla, C. Britschgi, P. Vagenknecht, G. Dimopoulou, R. Kammler, S.P. Finn, S. Peters, R.A. Stahel
Journal: Journal of Thoracic Oncology (2023)